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ABSTRACT
Clinical choice of β2-adrenergic receptor agonists (β2-agonists) is based on the parameter of receptor selectiv-
ity, potency, and duration of action. The guidelines for asthma management describe nothing about intrinsic ef-
ficacy concerning the use of β2-agonists. Since intrinsic efficacy refers to the ability to activate β2-adrenergic re-
ceptors independent of agonist concentration, β2-adrenergic desensitization may be associated with intrinsic
efficacy. However, little is currently known whether chronic administration of high intrinsic efficacy drugs inter-
feres with the effects of β2-agonists as a reliever medication. In this review, the causal relationship between in-
trinsic efficacy and desensitization to β2-agonists is examined in tracheal smooth muscle using isometric ten-
sion records. Reasonable clinical use of these agonists based on these observations is discussed. When β2-
agonists intrinsic efficacy was measured as relaxation response (the maximum inhibitory effects against 1 µM
methacholine-induced contraction), their rank order was : isoproterenol = procaterol = formoterol > salbutamol
> salmeterol >> tulobuterol. Next, the subsequent response to short-acting β2-agonists (procaterol, salbutamol)
was examined after continuous exposure to long-acting β2-agonists (formoterol, salmeterol, tulobuterol). β2-
adrenergic desensitization induced by these long-acting β2-agonists was enhanced in proportion to their intrin-
sic efficacies. On the other hand, under the conditions of impairment of β2-adrenergic receptors, reduced re-
sponsiveness to these short-acting β2-agonists was enhanced in inverse proportion to the intrinsic efficacy. Al-
though the clinical relevance of these results is still unclear, our data may provide evidence that weak partial
agonists are useful as a controller medication, whereas full or strong agonists are useful as a reliever medica-
tion．
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INTRODUCTION
β2-Adrenergic receptor agonists ( β2-agonists ) are
widely used clinically to relax airway smooth muscle
and are the principal bronchodilator agents used to
treat bronchial asthma . Regular administration of
short-acting β2-agonists may cause not only a deterio-
ration of asthma control and an exacerbation of air-
way hyperreactivity, but also an accelerative decline
in lung function in patients with this disease.1 These
undesirable dysfunctions may be due to reduced re-
sponsiveness to short-acting β2-agonists elicited by
excessive exposure to these agents, a phenomenon
referred to as desensitization.2,3 Moreover, a decline
in β2-agonist activity is observed after prolonged ex-
posure to pro-inflammatory cytokines4-6 and lysophos-
pholipid7 that participate in the airway inflammation
of bronchial asthma. A postmortem study also has
shown that the response to β2-agonists in vitro is at-
tenuated in airway smooth muscle harvested from pa-
tients with fatal asthma.8 The impaired β2-adrenergic
action is a characteristic feature of patients with this
disease , and is an important problem in both the
pathogenesis and therapy．
Rapid- and short-acting β2-agonists suppress bron-
choconstriction and related sympotoms of acute
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asthma exacerbations, but do not inhibit airway in-
flammation and airway hyperreactivity . Treatment
with anti-inflammatory agents is more effective than
that with bronchodilator agents for long-term man-
agement of bronchial asthma . Although the anti-
inflammatory effects of long-acting β2-agonists are
still unclear in clinical use, the guidelines for asthma
prevention and management recommend daily ad-
ministration of long-acting β2-agonists as a controller
medication . The regular use of long-acting β2-
agonists in combination with inhaled glucocorti-
costeroid is considered to be beneficial to these pa-
tients according to the cross-talk between these two
receptors . 9,10 However , a few reports have demon-
strated that regular use of inhaled long-acting β2-
agonists results in desensitization of β2-adrenergic re-
ceptors even though these agonists are added to in-
haled glucocorticosteroid therapy.11,12 Little is essen-
tially known whether prolonged activation of β2-
adrenergic receptors is not harmful．
There are several parameters in characterizing the
interaction of an agent with receptors, such as affin-
ity, potency, and efficacy. However, β2-agonists are
just classified by onset and duration of action in the
guideline for asthma management. This current clas-
sification may be insufficient to establish safe admini-
stration of β2-agonists. Previously statistical correla-
tion between regular use of β2-agonists and asthma
mortality or morbidity has been reported.13 This dete-
rioration is considered to be due to desensitization of
β2-adrenergic receptors mediated by excessive ad-
ministration of β2-agonists of higher intrinsic effica-
cies, such as isoproterenol and fenoterol. We should
carefully reconsider how to use these agonists . In
this review, the relationship between intrinsic efficacy
and desensitization to β2-agonists is examined in de-
tail using airway smooth muscle, and in addition, rea-
sonable clinical use of these agents based on this ob-
servation is discussed．
MECHANISMS OF DESENSITIZATION OF β2-
ADRENERGIC RECEPTORS IN AIRWAY
SMOOTH MUSCLE
It is well known that response to β2-agonists is mark-
edly attenuated after continuous and repeated expo-
sure to the agonists in airway smooth muscle of hu-
mans14 and other animals . 15 Previous reports have
demonstrated the molecular mechanisms of desensi-
tization of β2-adrenergic receptors in various tis-
sues. 16,17 After exposure to β2-agonists for a short
term (less than 30 min) , the β2-agonist activity is
markedly attenuated via the phosphorylation of β2-
adrenergic receptors, resulting in an uncoupling from
the stimulatory GTP-binding (G) protein of adenylyl
cyclase, Gs. A longer-term exposure leads to down-
regulation of surface receptor number via internaliza-
tion of the receptor and its subsequent degradation.
Two types of protein kinases are responsible for the
receptor phosphorylation, i.e., 1) second messenger-
activated kinases such as the adenosine 3’, 5’-cyclic
monophosphate ( cAMP) -dependent kinase (PKA)
and 2) the second messenger-independent G protein-
coupled receptor kinases such as the β2-adrenergic
receptor kinase (βARK) and G protein-coupled recep-
tor kinases (GRKs ) . 18,19 Receptor phosphorylation
mediated by PKA occurs with low concentrations of β
2-agonists, leading to heterologous desensitization.20
On the other hand, high concentrations of β2-agonists
are required for activaton of βARK and GRKs, leading
to homologous desensitization.20 The former refers to
a reduced response to not only β2-agonists but also
other agents that elevate concentration of intracellu-
lar cAMP bypassing β-adrenergic receptors, such as
forskolin, theophylline, db-cAMP, and prostaglandin
(PG) E2. The latter refers to a specific reduced re-
sponse to β2-agonists while response to these other
agents remain intact．
In airway smooth muscle cells, intracellular cAMP
formation in response to isoproterenol is attenuated
after incubation with not only β2-agonists but also
other agents involving cAMP such as forskolin and
PGE2.21 An inhibition in cAMP formation is mediated
by heterologous desensitization. However, in airway
smooth muscle, relaxation induced by β2-agonists is
impaired after excessive exposure to these agonists,
whereas the reduced relaxation by β2-agonists does
not occur after excessive exposure to these cAMP in-
volving agents independent of β2-adrenergic recep-
tors.14,15 When desensitization of β-adrenergic recep-
tors is examined by measuring a biochemical re-
sponse (cAMP formulation), heterologous desensiti-
zation is observed. In contrast, when β2-adrenergic
desensitization is examined by measurering a physi-
ologic response (smooth muscle relaxation in vitro),
heterologous desensitization is not observed .
Interferon-γ inhibits the reduced relaxation by het-
erologous β2-adrenergic desensitization after expo-
sure to TGF-β1, but does not recover the reduced
cAMP formation by TGF-β1.6 There is a discrepancy
between cAMP formulation and relaxation concern-
ing the impairment of β2-adrenergic action. Hence, in
airway smooth muscle measurement of relaxation
needs to estimate accurately desensitization to β2-
agonists．
Forskolin needs to produce a large amount of
cAMP to cause an equivalent relaxation that is
achieved with isoproterenol by producing a small
amount of cAMP in airway smooth muscle.22 cAMP
formation in response to β2-agonists is not always as-
sociated with relaxation. Recently, it is generally con-
sidered that β2-agonists have the effects mediated by
not only cAMP-dependent but also cAMP-
independent processes. The discrepancy in causing
heterologous desensitization may be due to these
cAMP-independent pathways. Large conductance Ca
2+-activated K+ (KCa) channels, which are densely dis-
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Fig. 1　Schema of mechanisms underlying desensitization of β2-adrenergic receptors measured 
as a physiologic response (relaxation response) in airway smooth muscle. The reduced respon-
siveness to β2-agonists is not mediated by cAMP-dependent processes. The Gs/KCa channel 
stimulatory linkage and the Rho/Rho-kinase pathway activated by cAMP-independent processes 
are involved in this homologous β2-adrenergic desensitization. The former causes Ca2+ mobiliza-
tion, and the later causes Ca2+ sensitization. CTX: cholera toxin, Lyso-PC: lysophosphatidylcholi-
ne, VDC channels: voltage-dependent Ca2+ channels.
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tributed on the surface of the membrane,23 are partly
involved in the membrane hyperpolarization and re-
laxation induced by these agonists.24 These channels
are activated independently by the two pathways as
follows : 1) cAMP-dependent channel phosphoryla-
tion via PKA25 and 2) cAMP-independent channel ac-
tivation via the α-subunit of Gs.26 The GsKCa channel
stimulatory linkage is partly involved in the cAMP-
independent relaxation by β-agonists . Since β2-
agonists have two pathways, these agonists are much
more potent in relaxation of airway smooth muscle
than other agents involving cAMP that bypass β2-
adrenergic receptors.22
INVOLVEMENT OF Gs IN β2-ADRENERGIC
DESENSITIZATION IN AIRWAY SMOOTH
MUSCLE
After excessive exposure to β2-agonists , the inhibi-
tory effects of agents involving cAMP independently
of β2-adrenergic receptors are not attenuated ; on the
contrary those effects are significantly augmented.27
Moreover, β2-agonist activity is still intact after expo-
sure to PGE2, which activates Gs via its own receptor
which is different from β-adrenergic receptors. These
results indicate that after excessive exposure of air-
way smooth muscle to β2-agonists, relaxation induced
by these agonists is markedly diminished mediated
by homologous desensitization, not by heterologous
desensitization (Fig. 1). The reduced responsiveness
to β2-agonists is not affected even when the tissues
are exposed to β2-agonists for an extended period in
the presence of Rp-cAMP, a permeable inhibitor of
PKA, also indicating that the cAMPPKA processes
are not involved in β2-adrenergic desensitization
measured as a physiologic response.14,15 The recep-
torGs processes play an important functional role in
not only the β2-aderenergic action but also the β2-
adrenergic desensitization in airway smooth muscle.
β2-agonists are more potent in causing both relaxa-
tion and desensitization than other agents involving
cAMP bypassing β2-adrenergic receptors. This char-
acteristic is due to cAMP-independent pathways such
as the GsKCa stimulatory linkage . 14,15,22,26 Hence ,
measurement of cAMP formation without examina-
tion of relaxation response is not appropriate to an as-
sessment of β2-adrenergic action and desensitization
in airway smooth muscle．
As described above , the phosphorylation of β2-
adrenergic receptors elicits a fuctional uncoupling be-
tween the receptors and the Gs proteins . It is well
known that cholera toxin (CTX) irreversibly activates
Gs mediated by ADP-rybosylation of α-subunit with a
remarkable reduction of guanosinetriphosphatase ac-
tivity . When airway smooth muscle is treated with
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β2-adrenergic Desensitization by Efficacy
Intrinsic efi-
cacy (%)
EC50 (μM)β-agonists
100.00.0007Formoterol
100.00.005Procaterol
100.00.062Isoproterenol
81.40.041Salbutamol
62.40.096Salmeterol
34.6----Tulobuterol
Values of intrinsic eficacy of β2-agonists measured as a physiol-
ogic response in airway smooth muscle.  The values of intrinsic 
eficacy are expressed as the maximum percent inhibition for β2-
agonists against 1 μM methacholine-induced contraction in 
guinea pig tracheal smooth muscle.
Table 1　
CTX before continuous or repeated exposure to β2-
agonists, CTX causes an inhibition in a subsequent
reduction in the relaxation action by β2-agonists and
lysophosphatidylcholine in a concentration- and time-
dependent manner.7,14,15,28 This inhibitory action of
CTX is not affected in the presence of Rp-cAMP. The
reduced responsiveness to β2-agonists after repeated
exposure to the agonists is enhanced in the presence
of a selective inhibitor of KCa channels,14 and is asso-
ciated with an elevation in intracellular Ca2+ concen-
tration.29 On the other hand, the reduced responsive-
ness to β2-agonists after continuous exposure to the
agonists and lysophosphatidylcholine is not associ-
ated with an increase in intracellular Ca2+ concentra-
tion, and is antagonized by an inhibition in Rho, a
small G protein, in the presence of Y-27632, an inhibi-
tor of Rho-kinase, in a concentration-dependent man-
ner . 7 These results indicate that in airway smooth
muscle β2-adrenergic desensitization is due to Ca2+
mobilization mediated by suppression of the GsKCa
channel stimulatory linkage and to Ca2+ sensitization
induced by RhoRho-kinase pathways (Fig. 1). More-
over, an irreversible activation of Gs leads to preven-
tion of β2-adrenergic desensitization, independent of
cAMPPKA processes. If a complete dissociation be-
tween the receptors and G proteins occurs in the re-
duced responsiveness to β2-agonists, the activation of
Gs may have no effects on prevention of the desensiti-
zation of β2-adrenergic receptors. Impairment of Gs
activity may be involved in this phenomenon.
MEASUREMENT OF β2-ADRENERGIC IN-
TRINSIC EFFICACY
An agonist’s potency depends on its affinity for a re-
ceptor and on its intrinsic efficacy. Affinity refers to
the attraction between an agent and its receptors, and
intrinsic efficacy refers to the ability of an agent to ac-
tivate its receptors . Since the limited dose of β2-
agonists is inhaled as a bronchodilator therapy
against acute asthma exacerbations, affinity for the
receptors may be a relatively unimportant parameter
in taking the clinical effects of these agonists. In con-
trast, intrinsic efficacy may reflect the capability of β2-
agonists to activate the receptors in the clinical ad-
ministration. If the values of intrinsic efficacy are ac-
curately measured, it would be an important parame-
ter in a rational clinical use of β2-agonists. However,
international guidelines for asthma management have
never described anything about it．
Some agonists completely activate receptors, how-
ever others partially activate them. The former are re-
ferred to as a full agonist, and the latter are as a par-
tial agonist. Moreover, partial agonists are classified
into two subtypes, i.e. 1) its efficacy is lower (weak
partial agonists) and 2) its efficacy is higher (strong
agonists).30 Activation of β2-adrenergic receptors is
directly measured as a conformational change using
receptor fluorescence. Intrinsic efficacy is also meas-
ured indirectly as a response to activation of the post-
receptor signal transduction pathways (changing in
cAMP formation),31 and as a physiological response
(changing in smooth muscle relaxation in vitro and
airway resistance in vivo).32 Measurement of agonist
efficacy markedly depends on variable factors in the
target cells, such as receptor number and presence of
functional antagonism.33 Intrinsic efficacy of each ag-
onist is expressed by difference between Kd (the dis-
sociation constant : the dependency of receptor occu-
pancy on agonist concentration) and EC50 (agonist
concentration that produces 50% inhibition of the
maximal contraction).30,31 The values of Kd and EC50
are common parameters in affinity and potency of an
agonist, respectively. More efficacious agonists have
greater difference of these two parameters. Partial ag-
onists need to occupy a large fraction of receptors to
produce an equivalent effect that full agonists achieve
by occupying much less receptors. The ratio of the in-
trinsic efficacy of any two β2-agonists is expressed as
a fraction between 0 and 1, taking that of adrenaline
as 1．
Barber et al. have expressed values of intrinsic effi-
cacy by measuring receptor activation as a biochemi-
cal response to activation of cAMPPKA processes
using human embryonic renal and cultured murine
lymphoma cells other than airway smooth muscle
cells. Under this experimental condition, the rank of
order of intrinsic efficacies is : isoproterenol >
fenoterol = procaterol > formoterol > albuterol > sal-
meterol > tulobuterol.30,34 These results indicate that
procaterol can activate approximately 15 times more
β2-adrenergic receptors than tulobuterol when these
two agonists occupy the same number of receptors．
β-ADRENERGIC INTRINSIC EFFICACY IN
AIRWAY SMOOTH MUSCLE
β2-agonists are administrated to patients with asthma
for an improvement of airflow limitation via relaxation
of airway smooth muscle. Although medications for
asthma can be administered in different ways , the
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Fig. 2　Pre exposure to long-acting β2-agonists results in a reduction in the inhibitory ac-
tion of short-action β2-agonists against 1 μM methacholine-induced contraction in guinea 
pig tracheal smooth muscle. The relaxation responses were expressed as a percentage 
of the maximal relaxation produced by free Ca2+ solution.
＊: p < 0.05, ＊＊: p < 0.01.
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most advantageous route of administration of β2-
agonists is thought to deliver directly into airways via
inhalation. This route leads to the direct and rapid on-
set of action, and to avoidance of the systemic side ef-
fects. It is currently unclear whether β-agonists in-
hibit clinically the airway inflammation elicited by ac-
tivated eosinophils. Moreover, as described above, β2-
agonists have cAMP-independent pathways and there
are discrepancies between cAMP formation and re-
laxation induced by these agonists . Hence , in this
study β2-adrenergic intrinsic efficacy was expressed
as receptor activation based on smooth muscle re-
laxation. Isometric tension records demonstrate the
direct action of β2-agonists on airway smooth muscle
independent of indirect action via inflammatory cells,
similar to inhalation, because these agonists are di-
rectly applied to the strips in the organ bath. Recep-
tor number and functional antagonism have an affect
on measurement of agonist efficacy. However, these
two factors are probably not affected when the experi-
ments are performed under the condition that the in-
tact tissues are used and that an equivalent concen-
tration of antagonists is applied . According to the
methods similar to those described previously , iso-
metric tension was recorded using guinea pig tra-
cheal smooth muscle . 35 β2-agonists were cumula-
tively applied to the intact tissues pre contracted by 1
μM methacholine. The values of EC50 and the maxi-
mal effects in the concentration-inhibition curves for
a β2-agonist express its potency and efficacy, respec-
tively. The values of EC50 and the maximum percent
inhibition for these β2-agonists in the curves are
shown in Table 1. The order of potency (EC50) was :
formoterol > procaterol > isoproterenol = salbutamol
> salmeterol > > tulobuterol . Isoproterenol , for-
moterol, and procaterol caused the complete inhibi-
tion against 1 μM methacholine-induced contraction
(100% inhibition), indicating that these agents are full
agonists. In contrast salmeterol, salbutamol, and tu-
lobuterol did not cause complete inhibition under this
experimental condition, indicating that these agents
are partial agonists. The order of efficacy (the mini-
mum percent inhibition) was : isoproterenol = for-
moterol = procaterol > salbutamol > salmeterol > tu-
lobuterol. When the functional antagonism was inten-
sified by application of 10-fold higher concentration of
methacholine, isoproterenol caused complete relaxa-
tion against this contraction, but the maximal effects
in the curves for formoterol and procaterol were at-
tenuated. The values of the maximum percent inhibi-
tion for isoproterenol , formoterol , procaterol were
100, 59.4 ± 9.2, 71.9 ± 10.9%, respectively (data not
shown). Under these experimental conditions , for-
moterol and procaterol behave as partial agonists for
relaxation in comparison with isoproterenol. There-
fore, it is considered that isoproterenol is a full ago-
nist, and that procaterol and formoterol are strong ag-
onists. Our data are roughly consistent with the rank
order of intrinsic efficacy measured as a biochemical
response to the adenylyl cyclasecAMP pathway.30,34
RELATIONSHIP BETWEEN β2-ADRENERGIC
DESENSITIZATION AND AGONIST INTRIN-
SIC EFFICACY IN AIRWAY SMOOTH MUS-
CLE
Inhalation of procaterol or salbutamol, which has a
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β2-adrenergic Desensitization by Efficacy
Fig. 3　Causal relationship between intrinsic eficacy and desensi-
tization to β2-agonists. Induced impairment of β2-adrenergic func-
tion is intensified in proportion to values of intrinsic eficacy after 
excessive exposure to β2-agonists. The subsequent reduced re-
sponsiveness to β2-agonists is intensified in inverse proportion to 
them.
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rapid onset and short duration of action, is used clini-
cally as a reliever medication to suppress bron-
choconstriction elicited by acute asthma attacks. In-
halation of formoterol or salmeterol, which have dura-
tion of action lasting for approximate 12 hour, is given
twice daily as a controller medication in addition to in-
haled glucocorticosteroid therapy. A patch formula-
tion of tulobuterol, a sustained-release β2-agonist, also
is used as a controller medication because of a 24-
hour duration of action.36 To determine whether a
controller medication using β2-agonists leads to a re-
duction in the inhibitory effects of β2-agonists for a re-
liever medication against acute asthma exacerba-
tions, subsequent response to these rapid- and short-
acting β2-agonists was examined after exposure to
these long-acting β2-agonists in guinea pig tracheal
smooth muscle using isometric tension recording
(Fig. 2). When 0.1 μM formoterol, the intrinsic effi-
cacy of which is strong , was applied to the intact
strips for 10 min, subsequent inhibition by 0.03 μM
procaterol and 0.3 μM salbutamol against contraction
induced by 1 μM methacholine was markedly attenu-
ated. The values of percent inhibition for procaterol
were decreased from 87.4 ± 4.4 to 38.0 ± 10.7% (n = 8,
p < 0.05 ) . Those values for salbutamol were de-
creased from 77.4 ± 7.9 to 2.6 ± 0.9% (n = 8, p < 0.01).
After exposure to equi-molar salmeterol, the intrinsic
efficacy of which is moderate, for an equivalent time,
the inhibitory effects of salbutamol on 1 μM
methacholine-induced contraction were attenuated .
The value of percent inhibition for salbutamol was de-
cerased to 48.0 ± 8.2% (n = 8, p < 0.05). In contrast,
those effects of procaterol were not significantly at-
tenuated. Those values for procaterol before and after
exposure to salmeterol were 87.4 ± 4.4 and 81.7 ±
4.1%, respectively (n = 8, not significant). After expo-
sure to equi-molar tulobuterol , intrinsic efficacy of
which is weak, for an equivalent time, the inhibitory
effects of both procaterol and salbutamol on
methacholine-induced contraction were not attenu-
ated. Those values for procaterol and salbutamol after
exposure to tulobuterol were 83.0 ± 5.4 and 73.0 ± 6.6,
respectively (n = 8, each not significant). The rank or-
der of causing β2-adrenergic desensitization is : for-
moterol > salmeterol > tulobuterol. This rank order
was identical with that of intrinsic efficacy of β2-
agonists．
When receptor activation is measured as a relaxa-
tion response, β2-adrenergic desensitization occurs in
proportion to the strength of intrinsic efficacy of ago-
nists . In airway smooth muscle full agonists cause
more desensitization of the receptors, whereas partial
agonists cause less desensitization. These results are
consistent with those obtained by measurements of
biochemical responses to activation of the postrecep-
tor signal transduction pathways.30,34 Although PKA-
mediated phosphorylation by partial agonists is simi-
lar to that by strong and full agonists , βARK- and
GRKs- mediated phosphorylation by partial agonists
are less than that by strong and full agonists.33 Strong
and full agonists cause both homologous and het-
erologous desensitization, in contrast, partial agonists
primarily cause hetrologous desensitization . There-
fore, it is generally considered that partial agonists
are less potent in causing desensitization.37 Our re-
sults also indicate that cAMPPKA processes are not
involved in a reduction in the relaxant action of β-
agonists after excessive exposure to the agonists, and
that the reduced responsiveness to β2-agonists is me-
diated by homologous desensitization , not by het-
erologous desensitization in tracheal smooth muscle
(Fig. 1).
On the other hand, in inverse proportion to the
rank order of intrinsic efficacy, the reduced respon-
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siveness to salbutamol was intensified more than that
to procaterol after exposure to each of these long-
acting β-agonists (Fig. 2). The effects of full agonists
are not affected under the condition of either high or
low receptor density in the cell surface. In contrast,
the effects of partial agonists may be intact with high
receptor density, but the effects of these agonists are
attenuated as receptor number is lowered. When the
uncoupling of the receptors from Gs and the receptor
internalization occurs in airway smooth muscle, full
agonists can yield a full relaxation response, whereas
partial agonists cannot do so. In the presence of func-
tional antagonism (contractile agents), the maximal
effects of β2-agonists are attenuated because effects of
β2-agonists are antagonized by signal transduction
pathways of contractile agents, such as methacholine,
histamine, prostaglandins, and leukotrienes. Airway
contraction leads to a reduction in β2-adrenergic in-
trinsic efficacy. Hence, the effects of partial agonists
can be attenuated when an acute asthma attack oc-
curs．
RATIONAL CHOICE OF INHALED β2-
AGONISTS IN THE MANAGEMENT OF
BRONCHIAL ASTHMA
Since the induced desensitization to β2-agonists in-
creases as the values of intrinsic efficacy of agonists
are elevated, daily administration of strong and full
agonists may be harmful for long-term asthma man-
agement. Weak partial agonists are appropriate for
controller medications. On the other hand, as the val-
ues of intrinsic efficacy are lowered, the reduced re-
sponsiveness to β2-agonists increases by decreased
receptor density after excessive exposure to these ag-
onists and by functional antagonism . Inhalation of
weak partial agonists, taken as needed, may not be
beneficial for the management of acute asthma .
Strong and full agonists are appropriate for reliever
medications . Previous clinical trials have demon-
strated that regular inhalation of salmeterol and tu-
lobuterol (weak partial agonists) as controller medi-
cation results in sustained bronchodilation effects
throughout the observation periods,36,38,39 and that, in
contrast, regular inhalation of formoterol (a strong
agonist) results in reduced bronchodilation effect.40,41
These results support the idea that excessive admini-
stration of strong and full agonists causes more de-
sensitization of β2-adrenergic receptors in airway
smooth muscle than that of weak partial agonists .
When the inhibitory effects of β2-agonists on bron-
chial hyperresponsiveness are evaluated using the
methacholine challenge test, inhalation of formoterol
protects against methacholine-induced bronchocon-
striction in a dose-dependent manner , whereas sal-
meterol has a weaker protective effect . 38,42 Regular
inhalation of salmeterol (a weak partial agonist) does
not antagonize the response to rescue short-acting β2-
agonists , such as albuterol . 43,44 These clinical data
also demonstrated that strong and full agonists
should be used as needed to relieve asthma symp-
toms and weak partial agonists should be used regu-
larly to keep persistent asthma under control (Fig. 3).
CONCLUSIONS
The membrane-delimited, cAMP-independent Gs acti-
vation plays an important functional role in both the
physiologic response and desensitization to β-
agonists. The intrinsic efficacy of β2-agonists, which
is involved in an increase in Gs activity, is responsible
for causing desensitization to these agonists. In air-
way smooth muscle excessive exposure to β2-
agonists of high intrinsic efficacy gives rise to greater
desensitization of the receptors than that to these ag-
onists of low intrinsic efficacy . When the β2-
adrenergic receptor function declines under the con-
ditions of uncoupling from Gs, lowered receptor den-
sity, and functional antagonisms, β2-agonists of lower
intrinsic efficacy do not generate a full intracellular
signal , leading to a reduction in the relaxation re-
sponse to partial agonists. Although the clinical rele-
vance of our data is still unclear, they may provide the
evidence that β2-agonists with a long duration of ac-
tion and low intrinsic efficacy are optimal for the
maintenance therapy of bronchial asthma, and that
those agonists with rapid onset of action and high in-
trinsic efficacy are optimal for rescue therapy against
acute asthma attacks．
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